Study to Evaluate Adenosine 2A Receptor Agonist (Regadenoson) in Patients Undergoing Lung Transplantation
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the maximum safe dose and duration of regadenoson (Lexiscan) that
can be given to people who are having a lung transplant. Regadenoson will be given as a
continuous IV infusion. All participants in the study will receive a regadenoson infusion
beginning in the operating room during the lung transplant procedure. Participants will be
assigned a certain dose of regadenoson to be given over a 12 or 24 hour period.